The Investor Relations Podcast
Podcast Description: The Investor Relations Podcast
Joshua Wilson is a registered investment banking representative and a licensed real estate broker. The content of this podcast is for informational purposes only and should not be considered legal, financial, or compliance advice. This podcast is not a substitute for professional advice. All views and opinions expressed by the host and guests are their own and do not necessarily reflect the policies or positions of any regulatory agency, organization, or employer. Listeners are encouraged to consult their own compliance teams, legal counsel, or financial advisors to ensure adherence to applicable regulations, including SEC, FINRA, and other industry-specific requirements. This podcast does not constitute a solicitation or recommendation for any financial products or services.
Welcome to The Investor Relations Podcast, where we explore the complex and fascinating world of capital markets, regulatory compliance, and investor communication. This show is designed for Investor Relations professionals, registered investment bankers, financial advisors, and corporate executives who want to sharpen their skills, stay informed, and navigate today’s fast-paced financial environment with confidence.
Each episode features industry leaders sharing actionable insights and experiences on topics critical to investor relations, including:
•Learn about the details of IPOs, secondary offerings, and PIPEs.
•Best practices for roadshows and crafting investor presentations that comply with SEC regulations.
•How to engage with retail and institutional investors while adhering to Reg FD.
•The role of social media in investor relations: What’s permissible, and where to tread carefully.
•Key strategies for handling earnings calls, forward-looking statements, and material disclosures.
•Managing shareholder activism and navigating the challenges of modern corporate governance.
•Reporting: How to communicate environmental, social, and governance efforts effectively.
Why Listen?
Whether you’re preparing for a capital raise, leading communications for a public company, or ensuring your team remains compliant, this show provides real-world conversations and valuable connections to help you succeed.
Ideal Guest: Are you a professional managing investor relations for a public company, guiding a team through an IPO, or helping corporations navigate compliance in a highly regulated environment? If so, we’d love to feature your expertise. This is an opportunity to showcase your knowledge, expand your professional network, and contribute to the broader conversation around transparency and trust in capital markets.
What’s In It for You?
•Gain actionable strategies for engaging and communicating with investors.
•Understand the nuances of SEC compliance, Reg FD, and FINRA rules.
•Learn how to build investor trust and drive long-term shareholder value.
•Get behind-the-scenes insights into successful capital raises, IPOs, and secondary offerings.
•Be part of a community of professionals dedicated to improving transparency and effectiveness in investor relations.
Whether you’re an IR professional, investment banker, or financial advisor, The Investor Relations Podcast delivers the insights, strategies, and connections you need to excel in the world of capital markets.
Subscribe now and be part of the conversation shaping the future of investor relations. If you’re interested in being a guest, send us a direct message to share your expertise and join our growing network of professionals.
The Investor Relations Podcast
Biotech IR Across Development Stages
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
In this episode of The Investor Relations Podcast, Michael Loftus, Biotech Growth Architect and Family Office Strategist, breaks down how investor relations strategies must adapt across the different stages of a biotech company’s growth. Drawing on his experience in capital markets and life sciences, Michael explains how IR leaders and executives can communicate more effectively with investors depending on whether their company is early-stage, mid-stage, or preparing for commercialization.
The conversation highlights why investors often place their confidence in the team during early-stage development, how mid-stage companies should emphasize asset value and visibility through investor conferences, and what late-stage biotechs must do to showcase the real-world impact of their products. For biotech executives, IR professionals, and capital markets stakeholders, this episode offers a practical roadmap for aligning investor communications with company maturity.
#InvestorRelations #Biotech #LifeSciences #CapitalMarkets #BiotechInvesting #ShareholderEngagement
Connect with the Guest
- Company: https://www.poccap.com
- LinkedIn: https://www.linkedin.com/in/mikeloftusclinicaltrials/
- Podcast profile: View all of their episodes here
Connect with the Host
- Joshua Wilson LinkedIn: https://www.linkedin.com/in/joshuabrucewilson/
- The Investor Relations Podcast YouTube channel: https://www.youtube.com/@TheInvestorRelationsPodcast
Contact Link
https://www.theinvestorrelationspodcast.com/contact/
Disclaimer: Joshua Wilson is a licensed Florida real estate broker and holds FINRA Series 79 and Series 63 licensure. The content of this podcast is for informational and educational purposes only and should not be considered legal, financial, or compliance advice. All views and opinions expressed by the host and guests are their own and do not necessarily reflect the policies or positions of any regulatory agency, organization, or employer. Listeners should consult their own legal counsel, compliance teams, or financial advisors to ensure adherence to applicable regulations, including SEC, FINRA, and other industry-specific requirements. This podcast does not constitute a solicitation or recommendation for any financial products or services.
Let’s Connect on LinkedIn:
https://www.linkedin.com/in/joshuabrucewilson/
To Contact Us, Please Visit:
Joshua:
With biotech, right? Sometimes there are different phases in the stage of the company. What are some IR strategies for maybe the different phases or stages of a biotech company?
Michael Loftus:
Sure. When you're first starting out—let's say you're pre-clinical moving into clinical—I think you really need to highlight the team working on the project and the pipeline. People are still investing in the jockeys at that point. The assets are secondary, I think, at first. If you have the best team in the world, they can get a mediocre asset to market. Versus a team of maybe really excited, smart people who don’t really have any experience—they might not know the pitfalls and pratfalls of how to get through certain hurdles along the way. So I think you highlight the team and your experience.
If you're a little further advanced, I think you really need to focus on the asset value—what you're working on—and really get it out to the market through investment banking channels. There are a lot of great investment banking conferences that these companies can attend. Face-to-face connection is really good when you have something to invest in.
And then if you're late stage, obviously it’s about kicking out the product and showcasing what it really has behind it—the different aspects of how it can serve that patient population.
